We have shown that ST6GAL-1 mediates resistance to chemoradiotherapy in rectal cancer cell lines and increases after treatment in some PDX and organoid rectal cancer models and that it is present in some untreated human rectal adenocarcinomas. Here, ST6GAL1 is linked to rectal cancer.